Table 2 FDA approved ADCs for cancers treated with radiotherapy
ADC | Trade name | Approved indication | Receptor target | Linker | Drug payload | Drug action | DAR |
|---|---|---|---|---|---|---|---|
Brentuximab vedotin | Adcetris | Hodgkin Lymphoma, anaplastic large cell lymphoma | CD30 | Enzyme cleavable | MMAE | Microtubule inhibitor | 4 |
Trastuzumab emtansine | Kadcyla | HER2+ breast cancer | HER2 | Non-cleavable | DM1 | Microtubule inhibitor | 3.5 |
Polatuzumab vedotin | Polivy | DLBCL | CD79b | Enzyme cleavable | MMAE | Microtubule inhibitor | 3-4 |
Enfortumab vedotin | Padcev | Urothelial cancer | Nectin-4 | Enzyme cleavable | MMAE | Microtubule inhibitor | 4 |
Trastuzumab deruxtecan | Enhertu | HER2+ breast, NSCLC, gastric, esophageal cancers | HER2 | Enzyme cleavable | DXd | Topoisomerase I inhibitor | 8 |
Sacituzumab govitecan | Trodelvy | Triple negative breast, urothelial cancers | Trop-2 | Hydrolyzable | SN-38 | Topoisomerase I inhibitor | 7.6 |
Tisotumab vedotin | Tivdak | Cervical cancer | TF | Enzyme cleavable | MMAE | Microtubule inhibitor | 4 |
Loncastuximab tesirine | Zylonta | DLBCL | CD19 | Enzyme cleavable | PBD SG3199 | DNA crosslinker | 2.3 |
Disitamab vedotin | Aidixi | Gastric cancer | HER2 | Enzyme cleavable | MMAE | Microtubule inhibitor | 4 |
